Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bossuyt

Showing results (41-50 of 134) with videos related to

Pageof 14
Sort By:
Scandinavian Journal of Gastroenterology|December 30, 2021
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) studyAdriaan Volkers, Peter Bossuyt, Jitteke de Jong, et al.
Expert Review of Clinical Pharmacology|September 8, 2017
Management of patients with inflammatory bowel disease and spondyloarthritisLieven Pouillon, Peter Bossuyt, Joke Vanderstukken, et al.
United European Gastroenterology Journal|June 12, 2014
Comparison of six different calprotectin assays for the assessment of inflammatory bowel diseaseDelphine Labaere, Annick Smismans, August Van Olmen, et al.
Inflammatory Bowel Diseases|January 12, 2024
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort StudyDahham Alsoud, João Sabino, Denis Franchimont, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2020
Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple CentersLieven Pouillon, Thomas Remen, Caroline Amicone, et al.
Inflammatory Bowel Diseases|November 17, 2021
Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|June 17, 2021
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
The American Journal of Gastroenterology|November 12, 2020
Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIXPauline Rivière, Geert D'Haens, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|September 4, 2024
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's DiseaseJulian Panés, Edouard Louis, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|August 2, 2024
Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG StudyMiguel Regueiro, Monika Fischer, Peter Bossuyt, et al.
Pageof 14

Showing results (41-50 of 134) with videos related to

Sort By:
Pageof 14
Scandinavian Journal of Gastroenterology|December 30, 2021
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) studyAdriaan Volkers, Peter Bossuyt, Jitteke de Jong, et al.
Expert Review of Clinical Pharmacology|September 8, 2017
Management of patients with inflammatory bowel disease and spondyloarthritisLieven Pouillon, Peter Bossuyt, Joke Vanderstukken, et al.
United European Gastroenterology Journal|June 12, 2014
Comparison of six different calprotectin assays for the assessment of inflammatory bowel diseaseDelphine Labaere, Annick Smismans, August Van Olmen, et al.
Inflammatory Bowel Diseases|January 12, 2024
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort StudyDahham Alsoud, João Sabino, Denis Franchimont, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2020
Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple CentersLieven Pouillon, Thomas Remen, Caroline Amicone, et al.
Inflammatory Bowel Diseases|November 17, 2021
Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|June 17, 2021
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
The American Journal of Gastroenterology|November 12, 2020
Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIXPauline Rivière, Geert D'Haens, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|September 4, 2024
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's DiseaseJulian Panés, Edouard Louis, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|August 2, 2024
Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG StudyMiguel Regueiro, Monika Fischer, Peter Bossuyt, et al.
Pageof 14